theglobe_02 Criterium Logo Std Tag Line-2
JUNE 2018    A Monthly Review of Articles of Interest for the Clinical Community

This Month's Clinical Focus: ORTHO/MED DEVICES  >

 
  DIA Logo 2018
MEET US AT the 2018 DIA ANNUAL Meeting
JUNE 24-28 Boston MA  Chicago IL

CALL Ronny Schnel 310-619-6691

 

FDA Approval of RENOVA iStim™ Implantable Tibial Nerve Neuromodulator for Overactive Bladder 


FDA approved the Israeli company's pivotal study design for its RENOVA iStim™ system to support its marketing application in US.
 
RENOVA iStim™ is an innovative, battery-less, leadless, miniature, implantable Tibial Nerve Neuromodulation System, for the management of overactive bladder (OAB), including urinary urge incontinence and symptoms of urgency-frequency. An estimated 66 million people in the EU and 43 million in the US suffer from OAB, a disease that adversely affects patient's quality of life.
FDA Logo
The OASIS pivotal trial (OverActive bladder StImulation System study) is designed to evaluate the safety and effectiveness of BlueWind's RENOVA iStim™ Tibial Stimulation System for the treatment of urinary urgency incontinence in patients who have failed or could not tolerate more conservative treatments. The endpoints of the OASIS pivotal study are similar to those published in clinical literature for urinary dysfunction. Study analysis will be focused, among other things, on the proportion of responders to tibial therapy at six months post-implant based on reduction in urinary urgency incontinence episodes from the patient's baseline diary. Safety and durability of the effect will be assessed 12 months post implantation.
 
BlueWind Medical expects patient enrollment to commence in early 2019, with an overall target of 250 patients to be implanted with RENOVA iStim™ at up to 25 medical centers, in several European countries, including the UK, Netherlands, Belgium and Germany.
 
On June 15 2016, a CE Mark was granted to BlueWind's RENOVA iStim™ system for the treatment of OAB. In a pilot clinical study conducted in Europe, BlueWind Medical demonstrated the safety and performance of the RENOVA iStim™. Of the overall patient cohort, 70.6% of patients had =50% reduction in their symptoms or a return to normal voiding at the 6-month follow-up; this high rate of responders coincides with significant improvement in all aspects of OAB health related quality of life. At the 1-month follow-up after activation, a significant therapeutic impact was observed, with more than 50% of subjects reporting =50% symptoms relief.

SOURCE: Article usage courtesy of PRNewswire
 

First US Implantations of the Hintermann Series H2® Total Ankle Replacement Prosthesis

 
GenSight Biologics reported 2.5 years of follow-up data from its phase I/II clinical trial of GS010 in patients with Leber Hereditary Optic Neuropathy (LHON).
 
DT MedTech, LLC (DTM) announced the first Hintermann Series H2® Total Ankle Replacement Systems has successfully been implanted in patients in the United States. Surgeries were performed, implanting the two-component, semi-constrained total ankle replacement prostheses, at The Johns Hopkins Hospital in Baltimore, Maryland by Dr. James Ficke, Director of Orthopaedic Surgery and Orthopaedist-in-Chief, and at Lakewood Ranch Medical Center in Sarasota, Florida by Dr. James Cottom of Florida Orthopedic Foot and Ankle Center.
 
DTMedTech Total Ankle Replacement Device
 
The Hintermann Series H2® Total Ankle Replacement System is indicated to replace painful arthritic ankle joints due to primary osteoarthritis, post-traumatic osteoarthritis, or arthritis secondary to inflammatory disease (e.g., rheumatoid arthritis, hemochromatosis). The H2 may also be used as a revision for failed ankle replacements or non-union and mal-union of ankle arthrodesis. It is intended for cement use only in the US.
 
Prof. Beat Hintermann, world-renowned foot and ankle surgeon and developer of the H2, attended the surgeries and said, "I am extremely pleased to be here and observe the implantation of the first H2 ankles in the US. The surgeons did exemplary work and I am confident they will be very satisfied with their patients' outcomes. The H2 design is based on the Hintermann H3* mobile-bearing ankle which has 18 years of positive clinical outcomes. I'm sure these ankles will prove to be the preferred ankle replacement prostheses for surgeons and patients in the United States and around the world."   
 
Dr. James Cottom observes, "I believe this implant will be a game changer in ankle arthroplasty and think future clinical studies will demonstrate that it is in a class of its own."
 
SOURCE: Article usage courtesy of CenterWatch

Image credits: Implant device courtesy of DT MedTech, LLC

WHAT'S NEW AT CRITERIUM:
Current Global Studies

Ph II ORTHO - Knee Lesions
Ph II Pancreatic Cancer
Ph I/II Surgical Site Infections
Ph II Colorectal Cancer
Ph II Metastatic Breast Cancer
Ph II NSCLC
Ph I/II Myeloma (Amyloidosis)


SEE OUR STUDIES

CRITERIUM, Inc. Global CRO

Since 1991 Banner

OUR RESEARCH LIBRARY...
...is your access to continuing current information on successful clinical trials


FOLLOW OUR POSTS
See ALL POSTS at our BLOG

New Trial Reducing Use of Opioids for Pain

CRISPR Used to Restore Retinal Function

Orphan Drug Designation Granted for ALS

Beneficial Skin Bacteria Prevent Cancer

Huntington's Disease Kills Cancers

 
WATCH OUR VIDEOS
Airport Network - One Minute with Criterium CRO on Excellence in Clinical Trials
Featured at Travellers Hubs in US Airports


The Clinical Data Liaison: The Key to Better, Faster Clinical Trials
Featuring John M. Hudak, Prersident & Founder

LISTEN to OUR PODCASTS

 CNN Interview with John Hudak 
Featured at
Travellers Hubs in US Airports

Criterium Celebrates 20 Years
Featuring John M. Hudak, President & Founder

The Site-Centric CRO: Best Practices for Excellent Site Relationships 
Featuring Ed Jahn, Clinical Ops Specialist & Jaime Hudak, CDL

The Clinical Data Liaison: Better, Faster Trials
Featuring John M. Hudak
, President & Founder

Agile Clinical Trials and Real-Time Data
Featuring John M. Hudak
, President & Founder


READ OUR PUBLICATIONS

The Evolution of the Data Management Role: The Clinical Data Liaison   Mary Stefanzick

Critical Clinical Research Factors in the Down Economy  Lawrence Reiter, Ph.D

No Longer Lost In Translation
Dr. Gavin Leong in PharmaVOICE Magazine

Maintaining Clinical Operations: It's Just Good Business  PharmaVoice View on Clinical Operations


EDC Implementation 
Greg Bailey in PharmaVOICE, View on E-Solutions

Going Global 
John M. Hudak in Future Pharmaceuticals


Trials Limber Up 
John M. Hudak in Int'l Clinical Trials Magazine


VIEW OUR PRESENTATION
Criterium Capabilities Presentation
Corporate Overview, Trials & Experience

DOWNLOAD OUR BROCHURE

Criterium:  Connect - Communicate - Control
Understand How We Do What We Do



MORE OPPORTUNITIES:

OMDT Logo USA 2018

MEET US AT:
MED DEVICES USA 2018
JUL 11-12 Minneapolis MN

Call Ronny Schnel 310-619-6691


~ FOUNDED in 1991 ~
MANAGING SUCCESSFUL
Clinical Trials for 
over 25 years!
Resources are precious, time is the enemy, and results are paramount.

ACCELERATE
your clinical trials...
---------------------

CHANGE
the workflow paradigm...

- Information Management done right
- User-friendly technologies 
- Improved trial efficiencies
- Talented,
committed in-house staff

Proprietary technology solutions 
PROVEN to improve your 
clinical trial results.


- MAXIMUM client outcomes
- Small and AGILE Global CRO
- WIDE RANGE of Indications
- Expanded Oncology Consortia

 
Contact: John Hudak, President at jmhudak@criteriuminc.com
 
GET TO KNOW US!

CONTACT  US for an RFP or COMPETITIVE BID on your next project! 

FULL-SERVICE RESEARCH - TRIAL RESCUE SERVICES - PROJECT & DATA MANAGEMENT - BIOSTATISTICS
SITE SELECTION & MANAGEMENT - PROTOCOL DESIGN & CONSULTING - CLINICAL & MEDICAL MONITORING
CRF DESIGN - IxR & EDC - MEDICAL WRITING - SAFETY - REGULATORY CONSULTING - AND MORE!

About Criterium Inc.  Criterium Inc. www.criteriuminc.com is a global, full-service, technology-driven contract research organization that offers a unique mix of high-quality, innovative clinical research solutions for the biopharmaceutical, pharmaceutical, medical device, and CRO industries.